Literature DB >> 7986712

Expression of shared idiotypes by paraproteins from patients with monoclonal gammopathy of undetermined significance.

C E Kampe1, S Hart, R A Miller, A Lichtenstein, R A Kyle, J R Berenson.   

Abstract

We have previously demonstrated the expression of shared idiotypes by the paraproteins from approximately one-quarter of patients with multiple myeloma (MM). We have now investigated whether similar cross-reactivity is expressed in the paraproteins of patients with monoclonal gammopathy of undetermined significance (MGUS), using a panel of 32 monoclonal antibodies (MAB) generated against follicular B cell lymphomas. The paraproteins from 76/409 (19%) patients with MGUS reacted with at least one of 23 different anti-idiotypic antibodies used in this study. 18 MABs demonstrated reactivity with more than one patient's paraprotein. Moreover, 10 MABs reacted frequently (with 5-22 paraproteins). Over half (41/76) of the reactive patients' paraproteins reacted with more than one MAB from this panel. This frequency of anti-idiotypic reactivity was similar to that of previously studied patients with myeloma, chronic lymphocytic leukaemia (CLL), and follicular B-cell lymphomas. There was no correlation between specific anti-idiotypic reactivity and the propensity to develop serious disease (MM, macroglobulinaemia, amyloidosis, or other lymphoproliferative disorders) in patients with MGUS. These results suggest that MGUS is derived from cells producing antibodies that are similar to those of other B-cell malignancies and that the pattern of idiotype expression is irrelevant to malignant potential.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7986712     DOI: 10.1111/j.1365-2141.1994.tb06729.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  1 in total

1.  ["Benign" monoclonal gammopathy and chronic lymphatic leukemia in a patient with Noonan syndrome].

Authors:  J Riederer
Journal:  Med Klin (Munich)       Date:  1998-07-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.